STTR Phase I: An AI-Enhanced Angiographic System to Guide Endovascular Treatment of Intracranial Aneurysms

STTR 第一阶段：人工智能增强血管造影系统指导颅内动脉瘤的血管内治疗

• 批准号: 2111865
• 负责人: Mohammad Mahdi Shiraz Bhurwani
• 金额: $ 25.56万
• 依托单位: QAS.AI INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-15 至 2023-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2111865&HistoricalAwards=false
• 关键词: STTR; Phase; AI; Enhanced; Angiographic

The broader impact of this Small Business Technology Transfer (STTR) Phase I project falls within the larger scope of expanding artificial intelligence (AI) methods into health care applications. The application is focused on image guided endovascular surgical procedures for intracranial aneurysms (IA), which may cause subarachnoid hemorrhage, the most devastating type of hemorrhagic stroke. The current trends in treatment of aneurysms show that endovascular approach has become the mainstay procedure due to reduced surgical complications when compared with open skull surgery. Despite tremendous technological advances in devices and surgical instrumentation, as many as 30% of these lesions are not completely healed after the first surgical intervention, exposing patients to additional risks for complications due to multiple surgical procedures. The AI autonomous solution developed in this project will be the one of the first applications that provides intraoperative prognosis for six-month healing of an aneurysm after each surgical step to allow surgical adjustments, reducing the risk for ruptures and re-treatments from 30% to an estimated 5% and creating savings for the $65,000 in retreatments (roughly $1.95 B annually in the U.S.).This Small Business Technology Transfer (STTR) Phase I project will aim to develop a comprehensive and autonomous AI method that will provide intraoperative prognosis of complete healing for an IA at six months. In current clinical practice, neuro-interventionalists cannot guarantee successful healing of intracranial aneurysms immediately post-device placement. Treated patients have to wait a minimum of 3-6 months before their aneurysm is reassessed on medical imaging and the clinician decides if re-treatment is needed. During this critical time, patients are still at risk of rupture. In addition, re-treatments have higher risk to the patient as well as bear a financial burden on hospitals and insurance companies. The proposed algorithms will be fully integrated with surgical equipment and will allow dynamic angiographic analysis to derive physics-based parameters related to the nature of blood flow inside the aneurysm sac. These parameters are combined with a machine learning algorithm to provide a prediction as to whether the treatment is sufficient for a full healing.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业技术转让(STTR)第一阶段项目的更广泛影响属于将人工智能(AI)方法扩展到医疗保健应用的更大范围。其应用主要集中在图像引导下的血管内手术治疗颅内动脉瘤(IA)，这可能会导致蛛网膜下腔出血，这是最具破坏性的出血性中风类型。目前治疗动脉瘤的趋势表明，与开颅手术相比，血管内入路由于减少了手术并发症，已成为主要的治疗方法。尽管在设备和手术器械方面取得了巨大的技术进步，但这些损伤中多达30%在第一次手术干预后没有完全愈合，使患者面临由于多次手术而出现并发症的额外风险。在该项目中开发的人工智能自主解决方案将是首批应用之一，该解决方案将在每个手术步骤后提供动脉瘤六个月愈合的术中预测，以允许手术调整，将破裂和重新治疗的风险从30%降低到估计的5%，并为再治疗节省6.5万美元(在美国，每年约19.5亿美元)。这个小型企业技术转移(STTR)第一阶段的目标是开发一种全面和自主的人工智能方法，将在六个月内为IA提供完全愈合的术中预测。在目前的临床实践中，神经干预者不能保证支架置入后立即成功治愈颅内动脉瘤。接受治疗的患者必须至少等待3-6个月，然后才能通过医学成像重新评估他们的动脉瘤，临床医生将决定是否需要重新治疗。在这一危急时刻，患者仍有破裂的风险。此外，再次治疗对患者的风险更高，并给医院和保险公司带来经济负担。拟议的算法将与手术设备完全集成，并将允许动态血管造影分析得出与动脉瘤囊内血液流动性质相关的基于物理的参数。这些参数与机器学习算法相结合，以提供关于治疗是否足以完全愈合的预测。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。